NCT00002168已完成不适用
An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml
Bristol-Myers Squibb26 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 26
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.
详细描述
100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (26)
Loading locations...
相似试验
已完成
不适用
A Study to Compare the Effectiveness of Two Anti-HIV Drug CombinationsHIV InfectionsNCT00002430Merck Sharp & Dohme LLC220
已完成
2 期
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment FailureHIV InfectionsNCT00000918National Institute of Allergy and Infectious Diseases (NIAID)300
已完成
3 期
A Study to Compare Two Anti-HIV Drug CombinationsHIV InfectionsNCT00002447Hoffmann-La Roche146
撤回
2 期
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionHIV InfectionsNCT00006339National Institute of Allergy and Infectious Diseases (NIAID)
已完成
2 期
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirHIV InfectionsNCT00002423Glaxo Wellcome100